Global Digital Dose Inhaler Market Insights Forecasts to 2030
- The Digital Dose Inhaler Market was valued at USD 2.65 Billion in 2021.
- The market is growing at a CAGR of 15.5% from 2022 to 2030
- The global Digital Dose Inhaler Market is expected to reach USD 5.98 billion by 2030
- Asia Pacific is expected to grow the fastest during the forecast period
Get more details on this report -
The Global Digital Dose Inhaler Market is expected to reach USD 5.98 billion by 2030, at a CAGR of 5.98% during the forecast period 2022 to 2030.
The digital dose inhaler is a tool that allows patients to administer themselves by inhaling a predetermined dose of medication into their lungs in a brief burst of aerosolized medication. In-built sensors in digital inhalers monitor inspiratory flow and identify inhaler use in accordance with dose management and release. Metered dose inhalers (MDI) and dry powder inhalers (DPI) are two examples of the numerous types of digital dose inhalers that are offered on the market. Metered dose inhalers are the most used dose delivery method for treating respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), and others.
Impact of COVID 19 On Global Digital Dose Inhaler Market
With the onset of COVID 19 pandemic there has been an increase in the demand of medical supplies like personal protective equipment such as gloves, masks, and protective eyeglasses. With the increasing number of COVID 19 cases across the world, the requirement of medical supplies keep on increasing both from civil population and healthcare professionals for taking precautionary measures. The key market players have an opportunity to capitalize this rise in the demand of medical supplies in order to ensure adequate supply of personal equipment in the global market. In fact, the pandemic has resulted into the positive impact on the global digital dose inhaler market. Market for digital dose inhalers is impacted. This worsening pandemic situation has a negative impact on the supply chain and lowers the demand for digital dose inhaler devices, which has led to temporary industry closures and government announcements of lockdowns in various regions.
Key Driving Factors
The increasing technology advancements in the field of digital dose inhaler market is significantly revolutionising the inhalation therapy devices such as meter those inhalers integrated with an e-dose counter, internet-connected and compact inhalers, and others. The key market players are mainly focusing on the connectivity Technology in order to improve the patient medication adherence and to make sure that the appropriate dosage is being provided to the patients. Apart from this the increasing demand for technology enabled features such a seamless data transfer and patient tracking add the crucial elements that are anticipated to accelerate the market growth. Furthermore, the favourable reimbursement policies present to the patients in the form of Government sponsored Medicare plans, group association policies and individual insurance policies are anticipated to propel the treatment rates for asthma and other respiratory problems which is going to drive the overall market growth.
Global Digital Dose Inhaler Market Report Coverage
|Market Size in 2021:||USD 2.65 Billion|
|Forecast Period:||2021 - 2030|
|Forecast Period 2021 - 2030 CAGR:||15.5%|
|2030 Value Projection:||USD 5.98 Billion|
|Historical Data for:||2017 - 2020|
|No. of Pages:||212|
|Tables, Charts & Figures:||124|
|Segments covered:||By Product, By Type, By Region|
|Companies Covered:||Glenmark Pharmaceuticals Ltd., Novartis AG, Propeller Health, AstraZeneca Plc, Philips Respironics, Opko Health, Inc., Teva Pharmaceutical Industries Ltd., Gecko Health Innovations, Inc., Koninklijke Phillips N.V., GlaxoSmithKline Plc., AptarGroup Inc., Cipla, Inc.|
Get more details on this report -
On the other hand, increasing medication cost and high cost associated with devices, lack of awareness among people regarding advanced treatment and devices available for asthma are going to impede the market growth.
Metered Dose Inhaler segment is dominating the market with the largest market share over the forecast period
On the basis of product, the global digital dose inhaler market is segmented into metered dose inhaler and dry powder inhaler. Among these, metered dose inhaler segment is dominating the market with the largest market share over the forecast period. The growth is attributed due to the increasing healthcare expenditure levels, increasing cases of chronic heart diseases and availability of metered dose inhalers. Furthermore, the consistent technological advanced in the development of inhalation medication like mechanistic pharmacokinetic in electronic monitoring systems and nanotechnology based formulation along with high drug loads with smaller dose sizes are boosting the segmental growth.
Branded medication segment accounted the largest revenue share over the forecast period
Based on the type, the global digital dose inhaler market is segmented into branded medication and generics medication. Among these, the branded medication segment accounted the largest revenue share over the forecast period. This due to the fact that increasing expenditure levels of healthcare and increasing demand for ne respiratory medication development. In fact, the estimated penetration rate of these devices is attributed to the consistent advancement in the field of technology pertaining to the development of inhalation medicines as well as increasing number branded drug inhalation.
North America is dominating the market with the largest market share over the forecast period
Get more details on this report -
North America is dominating the digital dose inhaler market over the forecast period. This might be due to the intensive research and development efforts along with the widespread knowledge of the present high-tech breathing equipment. Additionally, a rise in the prevalence of respiratory disorders in both the young and old population will support market expansion.
Asia Pacific, on the other hand is witnessing the fastest market growth over the forecast period. The two main countries designated as centres for the respiratory devices sector are Japan and China. A number of key reasons, including increased ageing population burden, upward shift in total healthcare spending, and the quickly evolving healthcare industry, are anticipated to propel the expansion of the global digital dose inhaler market.
Recent Market Developments
- In September 2020, Teva Pharmaceuticals has launched the AirDuo Digihare and ArmonAir Digihaler inhalation powder. These are two digital maintenance inhalers for asthma patients.
List of Key Companies
- Glenmark Pharmaceuticals Ltd.
- Novartis AG, Propeller Health
- AstraZeneca Plc
- Philips Respironics
- Opko Health, Inc.
- Teva Pharmaceutical Industries Ltd.
- Gecko Health Innovations, Inc.
- Koninklijke Phillips N.V.
- GlaxoSmithKline Plc.
- AptarGroup Inc.
- Cipla, Inc.
This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the global Digital Dose Inhaler Market based on the below-mentioned segments:
Digital Dose Inhaler Market, Product Analysis
- Metered dose inhaler
- Dry powder inhaler
Digital Dose Inhaler Market, Type Analysis
- Branded Medication
- Generics Medication
Digital Dose Inhaler Market, Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Need help to buy this report?